Biocon rises and falls

about 1 year ago
No Image

Biocon announced today morning that its subsidiary Biocon Biologics has received the Drugs Controller General of India’s (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure.

Biocon Biologics has been granted licence for emergency use of CytoSorb in public interest by the Indian health regulator to treat COVID-19 patients who are 18 years of age or older. The licence will be effective until control of the COVID-19 outbreak in the country.

The Company has received approval from DCGI in Form MD-15 (Medical Device) for reducing pro-inflammatory cytokine levels in order to control the ‘cytokine storm’ and benefit COVID-19 patients who are in a critical condition.

The market is not giving this news too much weight. The stock, which had closed yesterday at Rs.358.60, opened flat and then rose briefly to an intraday high at Rs.363.10 but from there, it soon fell and is now trading closer to the day’s low point at Rs.354 levels.

Popular Comments

No comment posted for this article.